| Open-Label Extension Study of Upadacitinib in Adult Participants With Moderate to Severe Atopic Dermatitis |
Active, not recruiting |
Atopic Dermatitis |
NCT04195698 |
| Discontinuation of Methotrexate in Rheumatoid Arthritis Patients Achieving Clinical Remission by Treatment With Upadacitinib Plus Methotrexate |
Recruiting |
Rheumatoid Arthritis|JAK Inhibitor|Musculoskeletal Ultrasound|Biomarker |
NCT05121298 |
| A Study of Oral Upadacitinib Tablet Compared to Placebo in Adult Participants With Moderate to Severe Hidradenitis Suppurativa to Assess Change in Disease Symptoms |
Active, not recruiting |
Hidradenitis Suppurativa (HS) |
NCT04430855 |
| A Study to Assess Disease Activity in Adult Participants With Ankylosing Spondylitis Who Receive Upadacitinib in a Real-world Setting |
Recruiting |
Radiographic Axial Spondylarthritis (r-axSpA) |
NCT05094128 |
| A Study to Evaluate the Pharmacokinetics, Safety, and Tolerability of Upadacitinib in Pediatric Subjects With Polyarticular Course Juvenile Idiopathic Arthritis |
Recruiting |
Juvenile Idiopathic Arthritis (JIA) |
NCT03725007 |
| A Study to Evaluate Efficacy and Safety of Upadacitinib in Adult Participants With Axial Spondyloarthritis |
Active, not recruiting |
Spondyloarthritis |
NCT04169373 |
| A Study of Oral Upadacitinib Tablets to Assess Change in Disease State in Participants Aged 12-75 Years With Moderate to Severe Atopic Dermatitis in Brazil |
Withdrawn |
Atopic Dermatitis (AD) |
NCT04666675 |
| A Study of the Efficacy and Safety of Upadacitinib (ABT-494) in Participants With Moderately to Severely Active Ulcerative Colitis |
Completed |
Ulcerative Colitis (UC) |
NCT03653026 |
| A Study to Evaluate the Pharmacokinetics, Safety and Tolerability of Upadacitinib in Pediatric Participants With Severe Atopic Dermatitis |
Recruiting |
Atopic Dermatitis |
NCT03646604 |
| Evaluation of Upadacitinib in Adolescent and Adult Patients With Moderate to Severe Atopic Dermatitis (Eczema) |
Active, not recruiting |
Atopic Dermatitis |
NCT03569293 |
| Expanded Access to Upadacitinib |
No longer available |
Atopic Dermatitis (AD) |
NCT04159597 |
| A Study to Evaluate the Efficacy and Safety of Upadacitinib in Subjects With Takayasu Arteritis (TAK) |
Recruiting |
Takayasu Arteritis (TAK) |
NCT04161898 |
| A Study to Evaluate Upadacitinib in Combination With Topical Corticosteroids in Adolescent and Adult Participants With Moderate to Severe Atopic Dermatitis |
Active, not recruiting |
Atopic Dermatitis |
NCT03568318 |
| A Study Evaluating the Safety and Efficacy of Upadacitinib in Adults With Active Ankylosing Spondylitis |
Active, not recruiting |
Ankylosing Spondylitis (AS) |
NCT03178487 |
| A Study to Evaluate Safety of Upadacitinib in Combination With Topical Corticosteroids in Adolescent and Adult Participants With Moderate to Severe Atopic Dermatitis |
Active, not recruiting |
Atopic Dermatitis |
NCT03661138 |
| A Study to Assess the Change in Disease State in Adult Participants Being Treated With Oral Upadacitinib Tablets in Participants With Oligo- or Poly-artIcular Psoriatic Arthritis |
Recruiting |
Psoriatic Arthritis |
NCT04758117 |
| A Study With Upadacitinib (ABT-494) in Subjects From China and Selected Countries With Moderately to Severely Active Rheumatoid Arthritis Who Have Had an Inadequate Response to Conventional Synthetic Disease-Modifying Anti-Rheumatic Drugs (csDMARDs) |
Completed |
Rheumatoid Arthritis (RA) |
NCT02955212 |
| A Study to Assess Real-World Use, Safety, and Effectiveness of Oral Upadacitinib in Adult and Adolescent (>=12 Years Old) Participants With Atopic Dermatitis |
Recruiting |
Atopic Dermatitis |
NCT05081557 |
| A Study to Evaluate Upadacitinib in Adolescent and Adult Subjects With Moderate to Severe Atopic Dermatitis (Measure Up 2) |
Active, not recruiting |
Atopic Dermatitis |
NCT03607422 |
| Study to Evaluate Adverse Events and Change in Disease Activity With Oral Tablets of Upadacitinib in Adult Participants With Non-Segmental Vitiligo |
Recruiting |
Non-Segmental Vitiligo |
NCT04927975 |
| A Study to Evaluate the Long-Term Safety and Efficacy of Upadacitinib (ABT-494) in Participants With Ulcerative Colitis (UC) |
Enrolling by invitation |
Ulcerative Colitis (UC) |
NCT03006068 |
| A Study of the Efficacy and Safety of Upadacitinib (ABT-494) in Participants With Moderately to Severely Active Crohn's Disease Who Have Inadequately Responded to or Are Intolerant to Biologic Therapy |
Completed |
Crohn's Disease |
NCT03345836 |
| A Study of Oral Upadacitinib Tablets to Assess the Change in Disease Symptoms in Adult Canadian Participants With Moderate to Severe Rheumatoid Arthritis |
Recruiting |
Rheumatoid Arthritis (RA) |
NCT04574492 |
| A Study of Oral Upadacitinib Tablets to Assess Treatment Patterns, Achievement of Treatment Targets and Maintenance of Response in Adult Participants With Moderate to Severe Rheumatoid Arthritis |
Recruiting |
Rheumatoid Arthritis (RA) |
NCT04497597 |
| A Study to Assess Disease Activity in Adolescent and Adult Participants With Atopic Dermatitis Who Receive Oral Upadacitinib Tablets in a Real-World Setting |
Recruiting |
Atopic Dermatitis |
NCT05139836 |
| A Study to Compare Upadacitinib (ABT-494) to Placebo in Adults With Rheumatoid Arthritis on Stable Dose of Conventional Synthetic Disease-Modifying Antirheumatic Drugs (csDMARDs) With an Inadequate Response or Intolerance to Biologic DMARDs |
Active, not recruiting |
Rheumatoid Arthritis |
NCT02706847 |
| A Study to Evaluate the Safety and Efficacy of Upadacitinib in Participants With Giant Cell Arteritis |
Recruiting |
Giant Cell Arteritis (GCA) |
NCT03725202 |
| A Study Comparing Upadacitinib (ABT-494) to Placebo in Adults With Rheumatoid Arthritis on a Stable Dose of Conventional Synthetic Disease-Modifying Antirheumatic Drugs (csDMARDs) Who Have an Inadequate Response to csDMARDs Alone |
Active, not recruiting |
Rheumatoid Arthritis |
NCT02675426 |
| A Study to Evaluate ABT-494 (Upadacitinib) in Adults With Moderate to Severe Atopic Dermatitis |
Completed |
Atopic Dermatitis |
NCT02925117 |
| A Study to Compare Safety and Efficacy of Upadacitinib to Dupilumab in Adult Participants With Moderate to Severe Atopic Dermatitis |
Completed |
Atopic Dermatitis |
NCT03738397 |
| A Study of Oral Upadacitinib (RINVOQ) Tablets to Assess Adverse Events and Change in Disease Symptoms in Korean Adult Participants With Moderate to Severe Active Rheumatoid Arthritis |
Recruiting |
Rheumatoid Arthritis (RA) |
NCT04541810 |
| A Maintenance and Long-Term Extension Study of the Efficacy and Safety of Upadacitinib (ABT-494) in Participants With Crohn's Disease Who Completed the Studies M14-431 or M14-433 |
Enrolling by invitation |
Crohn's Disease |
NCT03345823 |
| A Study of the Safety of Oral Elsubrutinib Capsules and Oral Upadacitinib Tablets Given Alone or in Combination (ABBV-599) for Adult Participants With Moderately to Severely Active Systemic Lupus Erythematosus to Assess Change in Disease State |
Enrolling by invitation |
Systemic Lupus Erythematosus (SLE) |
NCT04451772 |
| A Study of the Change in Early and Sustained Pain Control in Radiographic Axial Spondylarthritis in Adult Participants Receiving Upadacitinib |
Recruiting |
Radiographic Axial Spondylarthritis (r-axSpA) |
NCT04846244 |
| A Study of the Efficacy and Safety of Upadacitnib (ABT-494) in Participants With Moderately to Severely Active Crohn's Disease Who Have Inadequately Responded to or Are Intolerant to Conventional and/or Biologic Therapies |
Active, not recruiting |
Crohn's Disease |
NCT03345849 |
| A Study to Evaluate the Long-Term Efficacy, Safety, and Tolerability of Repeated Administration of Upadacitinib (ABT-494) in Participants With Crohn's Disease |
Active, not recruiting |
Crohn's Disease (CD) |
NCT02782663 |
| A Study to Investigate the Safety and Efficacy of Elsubrutinib and Upadacitinib Given Alone or in Combination in Participants With Moderately to Severely Active Systemic Lupus Erythematosus (SLE) |
Active, not recruiting |
Systemic Lupus Erythematosus (SLE) |
NCT03978520 |
| A Study Comparing Upadacitinib (ABT-494) Monotherapy to Methotrexate (MTX) Monotherapy in Adults With Rheumatoid Arthritis (RA) Who Have an Inadequate Response to MTX (SELECT-MONOTHERAPY) |
Active, not recruiting |
Rheumatoid Arthritis |
NCT02706951 |
| A Study to Evaluate Adverse Events and Change in Disease State of Oral Upadacitinib in Adolescent Participants Ages 12 to <18 Years Old Diagnosed With Atopic Dermatitis (AD) |
Recruiting |
Atopic Dermatitis |
NCT05029895 |
| A Study to Compare Upadacitinib (ABT-494) Monotherapy to Methotrexate (MTX) Monotherapy in Adults With Rheumatoid Arthritis (RA) Who Have Not Previously Taken Methotrexate |
Active, not recruiting |
Rheumatoid Arthritis |
NCT02706873 |
| A Study to Evaluate the Safety and Efficacy of Upadacitinib (ABT-494) for Induction and Maintenance Therapy in Participants With Moderately to Severely Active Ulcerative Colitis (UC) |
Active, not recruiting |
Ulcerative Colitis (UC) |
NCT02819635 |
| A Study in Rheumatoid Arthritis Patients Who Have Completed a Preceding Study With ABBV-105 Given Alone or in Combination With Upadacitinib |
Terminated |
Rheumatoid Arthritis (RA) |
NCT03823378 |
| A Study to Investigate the Safety and Efficacy of ABBV-105 Alone or in Combination With Upadacitinib (ABBV-599 Combination) in Participants With Active Rheumatoid Arthritis |
Completed |
Rheumatoid Arthritis (RA) |
NCT03682705 |
| An Observational Study to Assess the Real-World Effectiveness of Upadacitinib in Adult Participants With Rheumatoid Arthritis |
Not yet recruiting |
Rheumatoid Arthritis |
NCT05170646 |
| A Study Comparing Upadacitinib (ABT-494) to Placebo and to Adalimumab in Adults With Rheumatoid Arthritis Who Are on a Stable Dose of Methotrexate and Who Have an Inadequate Response to Methotrexate |
Active, not recruiting |
Rheumatoid Arthritis |
NCT02629159 |
| A Study to Compare Upadacitinib (ABT-494) to Placebo in Adults With Rheumatoid Arthritis (RA) Who Are on a Stable Dose of Conventional Synthetic Disease-Modifying Anti-Rheumatic Drugs (csDMARDs) and Have an Inadequate Response to csDMARDs |
Active, not recruiting |
Rheumatoid Arthritis |
NCT02720523 |
| A Phase 3 Study to Compare Upadacitinib to Abatacept in Subjects With Rheumatoid Arthritis on Stable Dose of Conventional Synthetic Disease- Modifying Antirheumatic Drugs (csDMARDs) Who Have an Inadequate Response or Intolerance to Biologic DMARDs |
Active, not recruiting |
Rheumatoid Arthritis (RA) |
NCT03086343 |
| An Observational Study to Evaluate Impact of CRP-Level on Real World Effectiveness of Upadacitinib as Monotherapy or in Combination With MTX in Adult Participants With Rheumatoid Arthritis |
Active, not recruiting |
Rheumatoid Arthritis (RA) |
NCT04267536 |
| An Open-label Extension Study Evaluating the Safety and Efficacy of Upadacitinib (ABT-494) in Rheumatoid Arthritis Subjects |
Completed |
Rheumatoid Arthritis |
NCT02049138 |
| A Study Comparing Upadacitinib (ABT-494) to Placebo in Participants With Active Psoriatic Arthritis Who Have a History of Inadequate Response to at Least One Biologic Disease Modifying Anti-Rheumatic Drug |
Active, not recruiting |
Psoriatic Arthritis |
NCT03104374 |
| A Study Investigating the Efficacy and Safety of Upadacitinib (ABT-494) Given With Methotrexate (MTX) in Adults With Rheumatoid Arthritis Who Have Had an Inadequate Response to MTX Alone |
Completed |
Rheumatoid Arthritis |
NCT02066389 |
| A Study Comparing Upadacitinib (ABT-494) to Placebo and to Adalimumab in Participants With Psoriatic Arthritis Who Have an Inadequate Response to at Least One Non-Biologic Disease Modifying Anti-Rheumatic Drug |
Active, not recruiting |
Psoriatic Arthritis |
NCT03104400 |
| Early Changes in Pain, Disease Activity, and Ultrasound Evidence of Inflammatory Synovitis in Patients Receiving JAK-inhibitor vs. TNF-inhibitor Therapy for Active Rheumatoid Arthritis: A Feasibility Study. |
Not yet recruiting |
Rheumatoid Arthritis |
NCT05153200 |
| A Multicenter, Randomized, Double-Blind, Placebo-Controlled Study of ABT-494 for the Induction of Symptomatic and Endoscopic Remission in Subjects With Moderately to Severely Active Crohn's Disease Who Have Inadequately Responded to or Are Intolerant to Immunomodulators or Anti-TNF Therapy |
Completed |
Crohn's Disease |
NCT02365649 |
| Study To Assess Frequency Of Serious Infections In Clinical Practice In Japan For Adult Participants With Rheumatoid Arthritis Receiving Oral RINVOQ Tablets |
Recruiting |
Rheumatoid Arthritis (RA) |
NCT04340115 |
| Molecular Signatures in Inflammatory Skin Disease |
Recruiting |
Atopic Dermatitis|Psoriasis |
NCT03358693 |
| Results in Real Clinical Practice of Treatment of Moderate-severe Atopic Dermatitis |
Recruiting |
Dermatitis, Atopic |
NCT05078294 |
| A Study Investigating the Efficacy and Safety of ABT-494 Given With Methotrexate in Subjects With Rheumatoid Arthritis Who Failed Anti-Tumor Necrosis Factor (TNF) Biologic Therapy |
Completed |
Rheumatoid Arthritis |
NCT01960855 |
| COVID-19 VaccinE Response in Rheumatology Patients |
Not yet recruiting |
Rheumatoid Arthritis|Psoriatic Arthritis|Spondylarthritis |
NCT05080218 |
| A Study in Healthy Adults and Adult Subjects With Rheumatoid Arthritis to Evaluate the Safety, Tolerability and Pharmacokinetics After Multiple Doses of ABT-494 |
Completed |
Rheumatoid Arthritis |
NCT01741493 |
